These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 35223310)

  • 1. An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption.
    Kyriakos G; Diamantis E; Memi E; Elefsiniotis I
    Cureus; 2022 Jan; 14(1):e21536. PubMed ID: 35223310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11.
    Van J; Frias JP; Bonora E; Raha S; Meyer J; Jung H; Cox D; Konig M; Peleshok J; Bethel MA
    Diabetes Ther; 2021 Oct; 12(10):2783-2794. PubMed ID: 34514554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.
    Guo L; Zhang B; Hou J; Zhou Z
    Diabetes Ther; 2020 Aug; 11(8):1821-1833. PubMed ID: 32621083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
    Patel H; Munir K; Sutherland S; Karanikas CA; Konig M
    Diabetes Ther; 2019 Dec; 10(6):2321-2330. PubMed ID: 31605302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in the treatment of type 2 diabetes: impact of dulaglutide.
    Thompson AM; Trujillo JM
    Diabetes Metab Syndr Obes; 2016; 9():125-36. PubMed ID: 27217788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dulaglutide for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
    Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
    Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.
    Norrbacka K; Sicras-Mainar A; Lebrec J; Artime E; Díaz S; Tofé-Povedano S; Hernández I; Romera I
    Diabetes Ther; 2021 May; 12(5):1535-1551. PubMed ID: 33860927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data.
    Kugler AJ; Thiman ML
    Diabetes Metab Syndr Obes; 2018; 11():187-197. PubMed ID: 29780260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon-like peptide-1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once-weekly exenatide and liraglutide.
    Alatorre C; Fernández Landó L; Yu M; Brown K; Montejano L; Juneau P; Mody R; Swindle R
    Diabetes Obes Metab; 2017 Jul; 19(7):953-961. PubMed ID: 28181725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program.
    Jendle J; Grunberger G; Blevins T; Giorgino F; Hietpas RT; Botros FT
    Diabetes Metab Res Rev; 2016 Nov; 32(8):776-790. PubMed ID: 27102969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes.
    Clements J; Moore K; Shealy K
    Expert Rev Endocrinol Metab; 2015 Nov; 10(6):581-590. PubMed ID: 30289034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
    Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
    Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis.
    Dagenais GR; Rydén L; Leiter LA; Lakshmanan M; Dyal L; Probstfield JL; Atisso CM; Shaw JE; Conget I; Cushman WC; Lopez-Jaramillo P; Lanas F; Munoz EGC; Pirags V; Pogosova N; Basile J; Sheu WHH; Temelkova-Kurktschiev T; Raubenheimer PJ; Keltai M; Hall S; Pais P; Colhoun HM; Riddle MC; Gerstein HC
    Cardiovasc Diabetol; 2020 Nov; 19(1):199. PubMed ID: 33239067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.